DNA Damage Repair Investment Landscape

Overview

This page summarizes R&D investment signals for DNA damage repair therapies in neurodegenerative diseases. DNA repair decline is a key feature of aging and neurodegeneration, with impaired repair mechanisms contributing to neuronal dysfunction and cell death in Alzheimer's Disease, Parkinson's Disease, and related disorders.[@dna2020]

Portfolio Metrics

| Metric | Value |
|---|---:|
| Total tracked trials (DNA repair mods) | ~50 |
| Active trials (recruiting/active) | ~15 (30%) |
| Preclinical programs | ~40 |
| Clinical-stage programs | ~10 (20%) |

Mechanism Clusters

DNA damage repair in neurodegeneration spans several key mechanistic categories:

Key Mechanisms

1. PARP Inhibition (Poly ADP-Ribose Polymerase)

Target: [PARP1](/genes/parp1), PARP2

PARP inhibitors have shown neuroprotective effects in preclinical models of Alzheimer's Disease and Parkinson's Disease by reducing DNA damage accumulation and improving mitochondrial function.[@parp2011]

Key Programs:

• Eli Lilly / Mitsubishi Tanabe - Phase 2 programs in AD/PD
• University research programs - Multiple Phase 1/2 trials ongoing

2. Base Excision Repair (BER)

Targets: [OGG1](/genes/ogg1), [XRCC1](/genes/xrcc1), Pol beta

Overview

This page summarizes R&D investment signals for DNA damage repair therapies in neurodegenerative diseases. DNA repair decline is a key feature of aging and neurodegeneration, with impaired repair mechanisms contributing to neuronal dysfunction and cell death in Alzheimer's Disease, Parkinson's Disease, and related disorders.[@dna2020]

Portfolio Metrics

| Metric | Value |
|---|---:|
| Total tracked trials (DNA repair mods) | ~50 |
| Active trials (recruiting/active) | ~15 (30%) |
| Preclinical programs | ~40 |
| Clinical-stage programs | ~10 (20%) |

Mechanism Clusters

DNA damage repair in neurodegeneration spans several key mechanistic categories:

Key Mechanisms

1. PARP Inhibition (Poly ADP-Ribose Polymerase)

Target: [PARP1](/genes/parp1), PARP2

PARP inhibitors have shown neuroprotective effects in preclinical models of Alzheimer's Disease and Parkinson's Disease by reducing DNA damage accumulation and improving mitochondrial function.[@parp2011]

Key Programs:

• Eli Lilly / Mitsubishi Tanabe - Phase 2 programs in AD/PD
• University research programs - Multiple Phase 1/2 trials ongoing

2. Base Excision Repair (BER)

Targets: [OGG1](/genes/ogg1), [XRCC1](/genes/xrcc1), Pol beta

BER is the primary pathway for repairing oxidative DNA damage, which accumulates in aging [neurons](/entities/neurons). Enhancement of BER is a promising therapeutic strategy.[@base2017]

Key Programs:

• Academic/NIH programs - Preclinical and Phase 1
• Small molecule BER enhancers - In development

3. Homologous Recombination

Targets: [BRCA1](/genes/brca1), [BRCA2](/genes/brca2), RAD51

The HR pathway is critical for repairing double-strand breaks. Dysfunction in neuronal HR contributes to genomic instability in neurodegeneration.[@homologous2018]

Key Programs:

• Research-stage programs - Predominantly preclinical

4. ATM/ATR Signaling

Targets: [ATM](/genes/atm), [ATR](/genes/atr)

ATM and ATR are key DNA damage response kinases that coordinate repair, cell cycle arrest, and [apoptosis](/entities/apoptosis). Modulating these kinases may protect neurons from genotoxic stress.[@atmatr2020]

Key Programs:

• ATR inhibitors - Being explored in combination therapies
• ATM modulators - Preclinical development

Therapeutic Development Pipeline

| Stage | Programs | Focus |
|---|---|---|
| Discovery/Preclinical | ~40 | BER enhancers, PARP modulators |
| Phase 1 | ~5 | PARP inhibitors, DNA repair supplements |
| Phase 2 | ~5 | PARP inhibitors, combination therapies |
| Phase 3 | ~0 | - |

Gap Analysis

Underserved Areas

Investment Opportunities

• BER enhancers for early-stage AD
• PARP1-selective inhibitors with brain penetration
• DNA damage response modulators for PD
• Combination therapies (DNA repair plus disease-modifying)
• Biomarker development for patient stratification

Key Players

Pharmaceutical Companies

| Company | Programs | Stage |
|---|---|---|
| Eli Lilly | PARP inhibitors | Phase 2 |
| Mitsubishi Tanabe | PARP modulators | Phase 2 |
| AbbVie | DNA repair research | Preclinical |
| Biogen | DDR modulators | Discovery |

Academic/Research Institutions

| Institution | Focus Area |
|---|---|
| NIH (NIA, NINDS) | BER, PARP research |
| University of Pennsylvania | DNA repair in AD |
| Stanford University | ATM/ATR signaling |
| Cambridge University | Genomic instability in neurodegeneration |

Clinical Trial Landscape

Active Recruiting Trials

• Multiple Phase 1/2 trials evaluating PARP inhibitors in AD/PD
• Observational studies characterizing DNA damage biomarkers
• Combination therapy trials in early-stage disease

Cross-Linking to Mechanism Pages

• [PARP1 Gene Page](/genes/parp1)
• [ATM Gene Page](/genes/atm)
• [ATR Gene Page](/genes/atr)
• [BRCA1 Gene Page](/genes/brca1)
• [BRCA2 Gene Page](/genes/brca2)
• [OGG1 Gene Page](/genes/ogg1)
• [XRCC1 Gene Page](/genes/xrcc1)

See Also

• [DNA Damage Repair Mechanisms](/content/mechanisms)
• [Neurodegeneration Pathways](/mechanisms/)
• [Investment Landscape Overview](/investment/)

External Links

• [DNA Repair journal](https://www.sciencedirect.com/journal/dna-repair)
• [Nature Neuroscience](https://www.nature.com/neuro/)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving DNA Damage Repair Investment Landscape discovered through SciDEX knowledge graph analysis: